AVEO Oncology

1 Broadway, 14th Floor, Cambridge, MA 02142

Public
Healthcare & Pharmaceuticals - Biotechnology
around $2.5 - 5M
around 20 - 50
(617) 588-1960
(617) 995-4995


AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380... (Source: SEC reports)


Competitor - 1/8
Which company is more competitive with AVEO Oncology?




15 Contacts at this company
Tracey Gleason, PHR
Senior Director Human Resources ...
Jeanne Celiberti
Director Supply Chain
Benjamin Julian
Assistant Controller
Wayne Tan
Associate Director, Assistant Controller
Brad Bailey
Senior Vice President, Franchise Head ...
Ryan Bis
Director of Finance, Corporate Controller
Yanyu Zhang
Senior Associate Scientist
Darlene Wilson
Sr. Clinical Research Manager
John H. Johnson
Board Member

Aug 1, 2018 18:54:24
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, [...]

Aug 1, 2018 17:30:37
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, [...]

Jul 19, 2018 19:18:42
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today issued the following statement regarding its recently revised guidance [...]

Jul 19, 2018 17:30:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today issued the following statement regarding its recently revised guidance [...]

Mar 26, 2018 18:55:17
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following  [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.